Barbie Doll Drug

(redirected from Afamelanotide)
A synthetic alpha melanocyte stimulating hormone (a-MSH) being developed by Clinuvel, for skin implantion or injection, which stimulates melanocytess to produce more (protective) melanin
References in periodicals archive ?
The market opportunity for Clinuvel's afamelanotide for the UV-related disorders being evaluated by the company is estimated by the Royal Bank of Scotland (NYSE: RBS) to exceed seven million patients across the globe.
SurModics' biodegradable polymer drug delivery technology permits afamelanotide to be released in a sustained and controlled manner.
SurModics' biodegradable polymer drug delivery technology enables the drug afamelanotide to be released in a sustained and tightly controlled manner.
Safety and tolerability of afamelanotide was evaluated by measuring treatment-emergent adverse effects (AEs).
Two amino acids in -MSH have been changed to produce afamelanotide which has more potent biological effects and a much longer half life than naturally occurring -MSH.
An analogue of [eth]-MSH, afamelanotide is a linear peptide which activates eumelanin of the skin, the dark pigment which is known to provide photoprotective properties (offering skin protection against light and UV radiation).
SCENESSE (R) controls the release of its active ingredient, afamelanotide (16mg), in picogram concentration, one trillionth of a gram.
Drug Profiles discussed in this report include afamelanotide, Antibody for Autoimmune Disorders and Inflammation, DP-C006, Drugs to Target HSP27 for Autoimmune Disorders, HL-161, ofatumumab, PC-111, VAY-736, veltuzumab and others.
Known as Afamelanotide, it prevents the disease in fair-skinned people and lasts for two months, and avoids recurrence.
Following my article "Why bronzing jabs give me the needle" of February 6, 2009, which stated that Melanotan (an injectable unregulated drug which is bought over the internet by people hoping to improve their tan) contains afamelanotide, I have been asked by the Australian company Clinuvel, which develops afamelanotide, to make clear that afamelanotide is a drug being clinically tested on patients suffering from various skin disorders including cancer and is unrelated to the illegal and untested chemical substances offered by online vendors under the unofficial name "Melanotan I and II".
Currently, Clinuvel is in its final stages to complete testing of afamelanotide in Phase II and III trials in Australia and Europe.
Only two adverse events were more frequent during active treatment: nausea, which occurred 1-2 days post implant in 33% of patients when being treated with afamelanotide, compared with 18% of patients when being treated with placebo; and hot flushes, which were noted 1-2 days after afamelanotide implantation in 11% of patients, compared with just 1% with placebo.